Stephen Cohen, MD
Cardiology · Santa Ana, CANPI 1225031586
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.1% of the total across 258 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 16.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,449 and has fallen 96.0% since, to $58 in 2025.
Across 258 payments — averaging $23.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$1K
- Johnson & Johnson$851
- Novartis$615
- Merz North America, Inc.$531
- Amgen$415
- Merck$334
- plus $2K from 26 others
What the payments were for
- Food & beverage$5,63294%
- Education$3516%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 40 | $1,008 |
| Johnson & Johnson | 38 | $851 |
| Novartis | 36 | $615 |
| Merz North America, Inc. | 6 | $531 |
| Amgen | 17 | $415 |
| Merck | 19 | $334 |
| Boehringer Ingelheim | 16 | $268 |
| E.r. Squibb & Sons, L.L.C. | 14 | $262 |
| Novo Nordisk | 12 | $234 |
| Astellas Pharma US Inc | 3 | $215 |
| Abbott | 7 | $168 |
| Pfizer | 7 | $166 |
| Biotronik Inc. | 7 | $155 |
| Boston Scientific | 5 | $100 |
| Sanofi-aventis U.S. LLC | 4 | $89 |
| Impulse Dynamics (USA) Inc. | 4 | $78 |
| Kiniksa Pharmaceuticals, Ltd. | 3 | $66 |
| Heartflow, Inc. | 2 | $49 |
| Cardiva Medical, Inc. | 2 | $48 |
| Abiomed | 1 | $47 |
| Esperion Therapeutics, Inc. | 3 | $43 |
| AstraZeneca | 2 | $42 |
| Kestra Medical Technology Services, Inc. | 1 | $26 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $24 |
| Scpharmaceuticals Inc. | 1 | $23 |
| Bayer | 1 | $22 |
| Lexicon Pharmaceuticals, Inc. | 1 | $21 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
| Sanofi Pasteur Inc. | 1 | $19 |
| Recor Medical Inc | 1 | $18 |
| Alnylam Pharmaceuticals Inc. | 1 | $18 |
| Gilead | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Micra$165
- Advisa$153
- Claria MRI$140
- XARELTO$121
How this compares
$5,983 in reported general payments places this provider in the 80th percentile of 156 cardiology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 481 | $616,103 |
| XareltoRivaroxaban | 188 | $215,405 |
| Repatha SureclickEvolocumab | 71 | $70,730 |
| EntrestoSacubitril/Valsartan | 63 | $67,424 |
| JardianceEmpagliflozin | 19 | $22,496 |
| Praluent PenAlirocumab | 14 | $15,167 |
| Repatha SyringeEvolocumab | 15 | $14,045 |
| Ezetimibe | 463 | $13,255 |
| BrilintaTicagrelor | 12 | $12,819 |
| Metoprolol Succinate | 770 | $9,804 |
| Atorvastatin Calcium | 1,066 | $8,703 |
| Rosuvastatin Calcium | 378 | $5,709 |
| Nebivolol Hcl | 47 | $4,922 |
| Nitroglycerin PatchNitroglycerin | 86 | $4,464 |
| DiovanValsartan | 12 | $4,268 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $166 | $616,103481 claims |
| Johnson & JohnsonXarelto | $851 | $215,405188 claims |
| NovartisEntresto, Diovan | $615 | $71,69275 claims |
| Boehringer IngelheimJardiance | $268 | $22,49619 claims |
| AstraZenecaBrilinta | $42 | $12,81912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 156 cardiology providers in California.
Other cardiology in Santa Ana
- Anil ShahSanta Ana$49K
- Thomas KimSanta Ana$47K
- Amer ZarkaSanta Ana$6K
- Mahmoud Eslami-FarsaniSanta Ana$5K
- Bahram EslamiSanta Ana$4K
- Paul MeltzerSanta Ana$2K
- Norman LeporBeverly Hills$1.9M
- Sanjay KaulLos Angeles$1.1M
- Ramtin AgahMountain View$361K
- Jamshid MaddahiLos Angeles$59K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.